Search
mRNA-3351
go.drugbank.com/drugs/DB17718ExperimentalDeveloped by Moderna, it is currently being investigated as the treatment for Crigler-Najjar syndrome
Lometrexol
go.drugbank.com/drugs/DB12769InvestigationalLometrexol has been used in trials studying the treatment of Lung Cancer, Drug/Agent Toxicity by Tissue/Organ, and Unspecified Adult Solid Tumor, Protocol Specific.
Tandutinib
go.drugbank.com/drugs/DB05465InvestigationalApproximately 25 to 30 percent of all adult AML patients have a mutation of the FLT3 gene. The use of MLN518 to treat AML has been granted fast-track status by the U.S. Food and Drug Administration. … Tyrosine kinases are enzymes involved in several cellular processes and are known to be activated in cancer cells to drive tumor growth.
Ticarcillin
go.drugbank.com/drugs/DB01607ApprovedVet approvedWithdrawnAn antibiotic derived from penicillin similar to carbenicillin in action.
Seliciclib
go.drugbank.com/drugs/DB06195InvestigationalDeveloped by Cyclacel, seliciclib is being researched for the treatment of non-small cell lung cancer (NSCLC), leukemia, HIV infection, herpes simplex infection, and the mechanisms of chronic inflammation
Sifalimumab
go.drugbank.com/drugs/DB12773InvestigationalSifalimumab may suppress the abnormal immune activity associated with lupus by binding to multiple interferon-alpha subtypes seen in the serum of lupus patients.
LU-31130
go.drugbank.com/drugs/DB05828ExperimentalLU-31130 is a rapid acting therapy developed by H. Lundbeck A/S to treat Psychosis, Schizophrenia and Schizoaffective Disorders.
anti-alpha5Beta1-integrin antibody
go.drugbank.com/drugs/DB05870ExperimentalThe integrin alpha5beta1 has been shown to play a critical role during angiogenesis. anti-alpha5beta1 integrin antibody inhibits angiogenesis, including vessel formation induced by vascular endothelial
Xanthine
go.drugbank.com/drugs/DB02134InvestigationalIt is an intermediate in the degradation of adenosine monophosphate to uric acid, being formed by oxidation of hypoxanthine.
BB-301
go.drugbank.com/drugs/DB17011Investigational[A260112] Developed by Benitec Biopharma, BB-301 is being investigated for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD).[L47062] … BB-301 is a modified AAV serotype 9 (AAV9) capsid expressing a unique, single bifunctional construct promoting co-expression of both codon-optimized Poly-A Binding Protein Nuclear-1 (PABPN1) and two small